Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 90

1.

Clinical and mutational features of X-linked agammaglobulinemia in Mexico.

García-García E, Staines-Boone AT, Vargas-Hernández A, González-Serrano ME, Carrillo-Tapia E, Mogica-Martínez D, Berrón-Ruíz L, Segura-Mendez NH, Espinosa-Rosales FJ, Yamazaki-Nakashimada MA, Santos-Argumedo L, López-Herrera G.

Clin Immunol. 2016 Apr;165:38-44. doi: 10.1016/j.clim.2016.02.010.

PMID:
26960951
2.

Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.

Guo A, Lu P, Galanina N, Nabhan C, Smith SM, Coleman M, Wang YL.

Oncotarget. 2016 Jan 26;7(4):4598-610. doi: 10.18632/oncotarget.6727.

3.

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.

Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR.

N Engl J Med. 2016 Jan 28;374(4):323-32. doi: 10.1056/NEJMoa1509981.

4.

Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia.

Li X, Wang A, Yu K, Qi Z, Chen C, Wang W, Hu C, Wu H, Wu J, Zhao Z, Liu J, Zou F, Wang L, Wang B, Wang W, Zhang S, Liu J, Liu Q.

J Med Chem. 2015 Dec 24;58(24):9625-38. doi: 10.1021/acs.jmedchem.5b01611.

PMID:
26630553
5.

Covalent targeting of acquired cysteines in cancer.

Visscher M, Arkin MR, Dansen TB.

Curr Opin Chem Biol. 2016 Feb;30:61-7. doi: 10.1016/j.cbpa.2015.11.004. Review.

PMID:
26629855
6.

Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism.

Rotin LE, Gronda M, MacLean N, Hurren R, Wang X, Lin FH, Wrana J, Datti A, Barber DL, Minden MD, Slassi M, Schimmer AD.

Oncotarget. 2016 Jan 19;7(3):2765-79. doi: 10.18632/oncotarget.6409.

7.

The importance of the tissue microenvironment in hairy cell leukemia.

Sivina M, Burger JA.

Best Pract Res Clin Haematol. 2015 Dec;28(4):208-16. doi: 10.1016/j.beha.2015.09.006. Review.

PMID:
26614899
8.

Historical overview of hairy cell leukemia.

Andritsos LA, Grever MR.

Best Pract Res Clin Haematol. 2015 Dec;28(4):166-74. doi: 10.1016/j.beha.2015.10.018. Review.

PMID:
26614894
9.

β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.

Thompson PA, O'Brien SM, Xiao L, Wang X, Burger JA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG.

Cancer. 2016 Feb 15;122(4):565-73. doi: 10.1002/cncr.29794.

PMID:
26588193
10.

Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.

Nagel D, Bognar M, Eitelhuber AC, Kutzner K, Vincendeau M, Krappmann D.

Oncotarget. 2015 Dec 8;6(39):42232-42. doi: 10.18632/oncotarget.6273.

11.

Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation.

Yeomans A, Thirdborough SM, Valle-Argos B, Linley A, Krysov S, Hidalgo MS, Leonard E, Ishfaq M, Wagner SD, Willis AE, Steele AJ, Stevenson FK, Forconi F, Coldwell MJ, Packham G.

Blood. 2016 Jan 28;127(4):449-57. doi: 10.1182/blood-2015-07-660969.

PMID:
26491071
12.

CD19 controls Toll-like receptor 9 responses in human B cells.

Morbach H, Schickel JN, Cunningham-Rundles C, Conley ME, Reisli I, Franco JL, Meffre E.

J Allergy Clin Immunol. 2016 Mar;137(3):889-98.e6. doi: 10.1016/j.jaci.2015.08.040.

PMID:
26478008
13.

Prevalence of BTK mutations in male Algerian patterns with agammaglobulinemia and severe B cell lymphopenia.

Boushaki S, Tahiat A, Meddour Y, Chan KW, Chaib S, Benhalla N, Smati L, Bensenouci A, Lau YL, Magdinier F, Djidjik R.

Clin Immunol. 2015 Dec;161(2):286-90. doi: 10.1016/j.clim.2015.09.011.

PMID:
26387629
14.

Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer.

Kokabee L, Wang X, Sevinsky CJ, Wang WL, Cheu L, Chittur SV, Karimipoor M, Tenniswood M, Conklin DS.

Cancer Biol Ther. 2015;16(11):1604-15. doi: 10.1080/15384047.2015.1078023.

15.

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells.

Wu H, Wang A, Zhang W, Wang B, Chen C, Wang W, Hu C, Ye Z, Zhao Z, Wang L, Li X, Yu K, Liu J, Wu J, Yan XE, Zhao P, Wang J, Wang C, Weisberg EL, Gray NS, Yun CH, Liu J, Chen L, Liu Q.

Oncotarget. 2015 Oct 13;6(31):31313-22. doi: 10.18632/oncotarget.5182.

16.

Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).

Cramer P, Langerbeins P, Eichhorst B, Hallek M.

Eur J Haematol. 2016 Jan;96(1):9-18. doi: 10.1111/ejh.12678. Review.

PMID:
26332019
17.

Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia.

Pillinger G, Abdul-Aziz A, Zaitseva L, Lawes M, MacEwan DJ, Bowles KM, Rushworth SA.

Sci Rep. 2015 Aug 21;5:12949. doi: 10.1038/srep12949.

18.

BTK gene targeting by homologous recombination using a helper-dependent adenovirus/adeno-associated virus hybrid vector.

Yamamoto H, Ishimura M, Ochiai M, Takada H, Kusuhara K, Nakatsu Y, Tsuzuki T, Mitani K, Hara T.

Gene Ther. 2016 Feb;23(2):205-13. doi: 10.1038/gt.2015.91.

PMID:
26280081
19.

Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.

Chakraborty R, Kapoor P, Ansell SM, Gertz MA.

Expert Rev Anticancer Ther. 2015;15(10):1143-56. doi: 10.1586/14737140.2015.1071668. Review.

PMID:
26196236
20.

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.

Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA.

JAMA Oncol. 2015 Apr;1(1):80-7. doi: 10.1001/jamaoncol.2014.218.

Items per page

Supplemental Content

Loading ...
Support Center